AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00769028
Recruitment Status : Unknown
Verified August 2011 by Daval International Limited.
Recruitment status was:  Active, not recruiting
First Posted : October 8, 2008
Last Update Posted : August 18, 2011
Information provided by:
Daval International Limited

Brief Summary:
To study the safety and tolerability of a hyperimmune goat serum product (AIMSPRO) in the treatment of systemic sclerosis (SSc) through a period of 26 weeks of study participation. The secondary objective of the study is to assess the efficacy of AIMSPRO as a therapeutic agent for SSc using inter alia the SSc-HAQ questionnaire and the modified Rodnan skin score.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Drug: Hyperimmune caprine serum Drug: Albumin Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo-Controlled Pilot Study of Safety and Tolerability of AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Study Start Date : December 2008
Actual Primary Completion Date : February 2011
Estimated Study Completion Date : September 2011

Arm Intervention/treatment
Experimental: AIMSPRO Drug: Hyperimmune caprine serum
Subcutaneous injection of serum, 1ml twice weekly for 6 months
Other Names:
  • Ceremben
  • Hyperimmune goat serum

Placebo Comparator: Placebo Drug: Albumin
Subcutaneous injection of albumin, 1ml twice weekly for 6 months
Other Name: Placebo

Primary Outcome Measures :
  1. Modified Rodnan Skin Score [ Time Frame: Baseline, Week 6 and Week 26 ]

Secondary Outcome Measures :
  1. Scleroderma Health Assessment Questionnaire [ Time Frame: Baseline, Week 6 and Week 26 ]
  2. Scleroderma UK Functional Score [ Time Frame: Baseline, Week 6 and Week 26 ]
  3. Patient and Physician Global Assessment (VAS) [ Time Frame: Baseline, Week 6 and Week 26 ]
  4. SF-36 (Short form 36) [ Time Frame: Baseline, Week 6 and Week 26 ]
  5. MRC Sum Score [ Time Frame: Week 0, Week 6 and Week 26 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must fulfill 1980 Preliminary Classification Criteria for systemic sclerosis of the American Rheumatism Association
  • Diffuse cutaneous SSc, as evidenced by skin sclerosis proximal to the elbows or knees and absence of the anti-centromere autoantibody
  • At least three years must have elapsed since the first non-Raynaud's manifestation
  • Men and women of childbearing potential must use adequate birth control measures for the duration of the study and should continue such precautions for six months after receiving the last injection of AIMSPRO.
  • Screening laboratory test results:

Hemoglobin > 8.5 g/dL WBC > 3.5 x 10^9/L Neutrophils > 1.5 x 10^9/L Platelets > 100 x 10^9/L SGOT (AST) and alkaline phosphatase levels must be within twice the upper limit of normal range for the laboratory conducting the test.

  • Patient must be able to adhere to the study visit schedule and other protocol requirements
  • Patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures
  • No radiological evidence of malignancy, infection or (previous) tuberculosis in a chest radiograph performed within three months prior to the first injection of study drug

Exclusion Criteria:

  • Women who are pregnant, nursing, or planning pregnancy within one and a half years after screening (i.e., approximately six months following last injection of study drug).
  • Use of any investigational drug within one month prior to screening or within five half-lives of the investigational agent, whichever is longer.
  • Use of a putative disease modifying drug (potential immunosuppressive drug) within one month of screening.
  • Treatment with any therapeutic agent targeted at reducing TNF (e.g., infliximab, pentoxifylline, thalidomide, etanercept, etc.) within three months of screening.
  • Previous administration of AIMSPRO.
  • History of known allergy to animal proteins.
  • Serious infections (such as pneumonia or pyelonephritis) in the previous three months. Less serious infections (such as acute upper respiratory tract infection [colds] or simple urinary tract infection) should be monitored to their conclusion or treated, as appropriate, prior to inclusion.
  • Active hepatitis-B or hepatitis-C.
  • Active tuberculosis.
  • Patients with opportunistic infections, including but not limited to evidence of active cytomegalovirus, active Pneumocystis carinii, Aspergillosis, histoplasmosis or atypical mycobacterium infection, etc, within the previous six months.
  • History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.
  • Known recent substance abuse (drug or alcohol).
  • Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period.
  • Presence of a transplanted organ (with the exception of a corneal transplant > three months prior to screening).
  • Patients receiving immunosuppressive therapy within one month of screening.
  • Patients with malignancy within the past five years.
  • Signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematologic, gastrointestinal, endocrine, pulmonary, cardiac or neurological disease (including demyelinating diseases such as multiple sclerosis).
  • Patients who, within the past three months, have had either a myocardial infarction, uncontrolled congestive cardiac failure, unstable angina, uncontrolled systemic hypotension or uncontrolled systemic hypertension.
  • Patients who have screening laboratory values which deviate 20% or more from the upper or lower limits of normal or which are considered to be clinically significant to the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00769028

United Kingdom
Centre for Rheumatology and Connective Tissue Diseases, Lower Ground Floor, Royal Free Hospital NHS Trust, Hampstead
London, United Kingdom, NW3 2QG
Sponsors and Collaborators
Daval International Limited
Principal Investigator: Christopher P Denton, PhD FRCP Royal Free Hospital NHS Trust

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Christopher Denton, Royal Free Hospital NHS Trust Identifier: NCT00769028     History of Changes
Other Study ID Numbers: DISS01
First Posted: October 8, 2008    Key Record Dates
Last Update Posted: August 18, 2011
Last Verified: August 2011

Keywords provided by Daval International Limited:
Systemic sclerosis
Diffuse cutaneous systemic sclerosis
Hyperimmune caprine serum
Goat Serum

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases